Pfizer: 5 to 11-Year-Old Children’s Vaccine is Rxpected to Receive EUA in Autumn and Winter
Scott Gottlieb, a member of Pfizer‘s board of directors and former director of the US Food and Drug Administration (FDA), told CNBC on Monday (30th) that the Pfizer/BioNTech vaccine for children aged 5 to 11 will be approved by the FDA at the end of this fall or early winter. Emergency Use Authorization (EUA).
Gottlieb said that Pfizer’s vaccine data for this age group of children should be announced in September and sent to the FDA that month, but he said that he may not apply for EUA until October.
Gautrib said: “If the FDA adheres to the normal review process, in terms of its review of EUA applications, it will take about 4 to 6 weeks to review, so the time will probably fall within the interval between the end of autumn and the beginning of winter.”